Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Acetylglycinamide chloral hydrate** is an orally administered sedative-hypnotic molecular complex containing chloral hydrate and N-acetylglycine in a 1:1 ratio. It is classified in the WHO ATC system as an aldehyde and derivative hypnotic and sedative. Its central nervous system depressant activity is attributed principally to the chloral-hydrate component and its active metabolite trichloroethanol, which potentiates gamma-aminobutyric acid-mediated chloride currents at gamma-aminobutyric acid type A receptors. Public records indicate possible marketing outside the United States, but do not establish a current approval or marketed brand. ([drugs.ncats.io](https://drugs.ncats.io/drug/6WZ3595RLZ))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylglycinamide chloral hydrate.